|
|
|
| 1903 |
| - |
von Tappeiner tried topical eosin and exposure to sunlight in an attemt to treat skin cancer. |
| 1913 |
| - |
Friedrich Metz-Beyer administered a porphyrin to himself and became photosensitive. |
| 1950s |
| - |
It was discovered that human cancer cells could take up porphyrins and become photosensitive. |
| 1980s |
| - |
The interest in PDT grew substantially. Clinical trials were performed but general photosensitivity of the patients was a problem. |
| 1993 |
| - |
The first report on clinical use of 5-aminolevulinic acid (ALA) for precursor-based PDT was published. |
| - |
Photocure was founded. |
| 1995 |
| - |
The first patent application on modified ALA was filed. |
| 2001 |
| - |
Photocure’s first product, Metvix, was approved in Europe and a licensing agreement was signed with Galderma. |
| 2005 |
| - |
Photocure’s second product Hexvix was approved in all EU/EEA countries. |
| 2006 |
| - |
Licencing agreement for Hexvix was signed with GE Healthcare. |
|
|
|